Summary.-Local tumour control has been determined at 150 days after single doses of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radiosensitizer Ro-07-0582. The dose required to control 500/ of the tumours (TCD50) was reduced from 4380 to 2410 rad, yielding an enhancement ratio of 1-82 i 0-07 s.e.mean. This compares favourably with the corresponding single dose gain factor for fast neutrons, which was about 1 -7.
THE PRESENCE of hypoxic and therefore radioresistant cells in tumours has been suggested as a possible cause of failure to eradicate some tumours using radiotherapy (Fowler, 1972 , gives a recent review). The most likely explanation for the existence of hypoxic tumour cells is that oxygen is rapidly used up by metabolism in cells through which it diffuses when it passes out of an inadequate capillary network, so that no oxygen is available to reach cells situated more than about 200 jim from capillaries (Thomlinson and Gray, 1955) . Compounds are being investigated which mimic the electron affinic property of oxygen, and might therefore be radiosensitizers, but which are capable of diffusing further from capillary vessels because they are not rapidly metabolized in the cells (Adams, 1973) .
Two promising compounds are at present under investigation. First, the 5-nitroimidazole, metronidazole (Flagyl, May & Baker Ltd, Dagenham, ), which gives sensitizing enhancement ratios (ER) of 158 in vitro (Asquith et al., 1974a, b; Chapman, Reuvers and Borsa, 1973 ) and 1.4 for cells made hypoxic in vivo (Denekamp, Michael and Harris, 1974) . Second, the 2-nitroimidazole, Ro-07-0582 (Roche Products Ltd, Welwyn Garden City, Herts (mol. wt 200.1)), which gives higher ERs of 2*5 in vitro (compared with the full oxygen ER of 2.8) and of about 2 in mouse skin made artificially hypoxic in vivo . In all the experiments just quoted, the concentration of drug in the medium (in vitro) and in serum (in vivo) at the time of irradiation was 5 mmol/l (850-1000 pg/ml) for both of the nitroimidazoles.
These enhancement ratios are sufficiently large for applications to radiotherapy in man to be seriously considered. The present experiments on local control of solid tumours in mice were therefore undertaken.
In solid experimental tumours in C3H mice breathing warm oxygen, local control was enhanced by metronidazole in the x-ray dose ratio of 1*4 (Begg, Sheldon and Foster, 1974 (Hill et al., 1970; Fowler et al., 1974) . The proportion of hypoxic cells present before irradiation under these conditions was known from other experiments to be about 10% (Fowler et al., unpublished) . This proportion is large enough to be the determining factor in response of the tumours to single doses of x-rays greater than 500 rad (assuming n = 2, Do = 130 rad and OER = 2-5 or 3)* or 700 rad (assuming n = 20 and Do and OER as before). The measured enhancement ratios, however, would be appreciably smaller for test doses of 1000 rad than for 2000 rad or higher doses. Mice were randomized into control or drug treated groups. Mice treated with the drug were given 1 mg/g body weight of Ro-07-0582 dissolved in warm, normal saline by intraperitoneal injection 30 min before irradiation started. Single doses of x-rays were given, the mice being turned through 180°halfway through the irradiation.
Irradiations were carried out as described previously (Fowler et al., 1974) , using 240 kV x-rays with h.v.l. 1-3 mm Cu and dose rate 240 rad/min. The mice were irradiated prone in a lead cradle with a hole 2-5 x 2-0 cm, through which the tumour hung freely during tangential irradiation with a horizontal beam. The dose rate at the centre of the thorax due to scattered radiation was measured as 22 rad per krad delivered to the tumour. After irradiation, the mice were revived with 0-5 mg per mouse of bemegride. The mice were kept for 150 days or until the treated tumours regrew to more than 6 mm mean diameter when they were scored as " recurred ". Mice were scored as " cured " if the tumours were less than 4 mm in mean diameter at 150 days after irradiation. There were no tumours between 4 and 6 mm in diameter at 150 days, which would have been scored as " ambiguous " and rejected from the analysis. The results were analysed using a computer programme developed by Dr E. H. Porter of the Glasgow Institute of Radiotherapeutics and Dr L. J. Peters of the Gray Laboratory. The programme assumes single-cell kinetics so that the tumour control probability is given by exp (-SN) where N is the initial number of clonogenic cells in the tumour and S is a surviving fraction. S is assumed to be an exponentially decreasing function of x-ray dose.
RESULTS
The results are shown in Table I Table II the fate of the experimental mice is shown: Ro-07-0582 appears slightly toxic at this high concentration, in contrast to metronidazole when used in conjunction with x-rays, with which no deaths that could be attributed to gut injury occurred . Eighty mice given a single dose of 1 mg/g of Ro-07-0582 showed no deaths up to 100 days. Although a significant difference had been demonstrated in TCD50 between the sexes in previous work (Fowler et al., 1974) , only small differences were found in the present results. The results presented are corrected to equal proportions of male and female mice; the corrections were small (Table I ). The ratio of TCD50s is 4380/2410 1*82 ± 0*07 s.e.mean.
The slopes of the curves relating tumour control to x-ray dose are significantly different (Fig.) . The corresponding D 0 values which provide the best fit to the data are 900 rad for x-rays only and 500 for x-rays plus Ro-07-0582. The value of 900 rad is consistent with many previous experiments using different radiosensitizers or fractionation schedules which were less effective (Fowler et al., 1947) . The ratio of the inverse slopes D 0 is 900/500-180 i 0-09 s.e.mean, which The incidence of metastases did not appear to be influenced by Ro-07-0582. In mice whose tumours had been controlled for 150 days, 4 of 57 mice receiving both Ro-07-0582 and x-rays developed visible metastases, compared with 5 of 54 mice receiving x-rays only. The incidence of metastases in mice with locally recurrent tumours was 6/41 and 2144 respectively (not significant difference, x2 -1.4). The incidence of metastases was not influenced by metronidazole either in the previously described experiment . Where tumours had been controlled for 150 days, 2/47 mice receiving x-rays and metronidazole developed metastases (compared with 1/20 in contemporaneous controls). The incidence for mice with locally recurrent tumours was 5/21 (cf. 4/14 in controls). These results are important in view of the finding that the drugs alone, without x-irradiation, caused a small delay in regrowth or reduction in size of the solid tumours Denekamp and Harris, unpublished 
DISCUSSION
The enhancement ratio ER -1-82 means that, in this tumour system, at a dose of 3800 rad the proportion cured rises from 3000 in control mice to nearly 100% in mice treated with 1 mg/g of (Fig.) . This value is similar to the ER of 1-9 found for the KHT sarcoma irradiated in air breathing mice and assayed in vitro (Rauth, unpublished) ; slightly less than the ER of 2. 1 for regrowth delay in the murine carcinoma NT (Denekamp and Harris, unpublished); and of 2 1 for the CBA mouse sarcoma F irradiated in vivo and assayed in vitro by Dr N. J. AIcNally; and of about 2 found by Dr L. J. Peters using local control of intradermal squamous cell carcinomata: but somewhat greater than the ER of 1.6 observed by Mr A. C. Begg using either regrowth or loss of incorporated 125IUdR after treating the CBA mouse sarcoma F with x-ray doses of 1000-1500 rad, (private communications). The latter enhancement may have been made low by the use of the relatively low x-ray test dose. All the results quoted are for air breathing mice given 1 mg/g of Ro-07-0582 intraperitoneally 20-60 min before irradiation.
These results show that a large increase in the proportion of tumours locally controlled can be obtained using radiosensitizing drugs and x-rays. The drug appears to diffuse out from capillaries to the hypoxic cells normally present in tumours and is effective as a sensitizer of these hypoxic cells in vivo. The enhancement ratios, like those for other sensitizers tested in vivo (Denekamp and Michael, 1972; Hewitt and Blake, 1970; Sheldon and Smith, 1974) (Rustia and Shubik, 1972) . No such effect was found in rats (Cohen et al., 1973 (Scharer, 1972) . No such neurological symptoms were seen with similar or larger daily doses of Ro-07-1051 in mice, rats, guinea-pigs or rabbits. Further, the differences in structure and solubility of the two compounds suggest that Ro-07-0582 should not be more toxic than Ro-07-1051. The toxicology of Ro-07-0582 itself obviously has to be investigated further.
CONCLUSIONS
The substantial enhancement ratio of 1.8 obtained for local control of the present solid tumour, using single doses of x-rays with 1 mg/g body weight of Ro-07-0582, compares well with the relative enhancement ratio of I 7 for hypoxic cells obtained for fast neutrons.
The disadvantage is that the large drug doses (1000 mg/kg) required to obtain the high enhancement ratios which have been measured in murine tumours do not at present appear to be feasible clinically. At the lower drug doses which might be clinically usable (50-100 mg/kg) the sensitization enhancement ratios would be lower; they are being measured in a variety of experimental tumour systems and ERs in the range 1 0-1-5 can be expected (Rauth, unpublished; Hewitt et al., personal communications 
